Clinical Trial

A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a Phase 1, first-in-human, open-label, multi-center study with the aim of exploring the safety, tolerability, PK, and preliminary anti-tumor activity of ANS014004 as a single agent in participants with locally advanced or metastatic solid tumors.
Protocol Amendment History 1 change
notable Trial sites expanded: 10 -> 15 locations 2026-04-18
Trial Details
NCT Number NCT06307795
Lead Sponsor Avistone Biotechnology Co., Ltd.
Conditions Locally Advanced or Metastatic Solid Tumors
Enrollment 63 participants
Start Date 2024-06-24
Primary Completion 2027-04 (estimated)
Study Completion 2027-10 (estimated)
Updated on ClinicalTrials.gov 2026-04-17